
Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904, New York, NY, 10019, United States
Overview
Charity focused on drug discovery for Alzheimer's disease.
Founded
1998
Deals · 12mo
2
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
MindImmune Therapeutics | Mar 2026Led | $5 MOther Equity | |
Circular Genomics | Dec 2025Participated | $15 MSeries A | |
C2N Diagnostics | Sep 2024Led | $7 MOther Equity | |
Neuro Therapia | Aug 2024Participated | $12 MSeries B | |
RetiSpec | Jul 2024Participated | $10 MSeries A | |
NeuroAge Therapeutics | Feb 2024Led | $0.25 MOther Equity | |
GliaPharm | Dec 2023Led | $4 MOther Equity | |
CuraSen Therapeutics | Oct 2023Led | $6 MOther Equity | |
ADmit Therapeutics | Oct 2023Participated | $6 MOther Equity | |
Astrocyte Pharmaceuticals | Aug 2023Participated | $6 MSeries B | |
Therini Bio | Apr 2023Participated | $36 MSeries A | |
Cognito Therapeutics | Mar 2023Participated | $73 MSeries B | |
MindImmune Therapeutics | Mar 2026Led | $5 MOther Equity | |
Circular Genomics | Dec 2025Participated | $15 MSeries A | |
C2N Diagnostics | Sep 2024Led | $7 MOther Equity | |
Neuro Therapia | Aug 2024Participated | $12 MSeries B | |
RetiSpec | Jul 2024Participated | $10 MSeries A | |
NeuroAge Therapeutics | Feb 2024Led | $0.25 MOther Equity | |
GliaPharm | Dec 2023Led | $4 MOther Equity | |
CuraSen Therapeutics | Oct 2023Led | $6 MOther Equity | |
ADmit Therapeutics | Oct 2023Participated | $6 MOther Equity | |
Astrocyte Pharmaceuticals | Aug 2023Participated | $6 MSeries B | |
Therini Bio | Apr 2023Participated | $36 MSeries A | |
Cognito Therapeutics | Mar 2023Participated | $73 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 6 |
| Series B | 0 | 3 |
| Other Equity | 8 | 2 |
| Grant | 1 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '16 | 1 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 1 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 2 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 1 |
| Sep '23 | 0 |
| Oct '23 | 2 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 20 |
| Space & Frontier Tech | 5 |
| Enterprise Software | 1 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 8 |
| $5M-$10M | 7 |
| $10M-$25M | 3 |
| $25M-$50M | 1 |
| $50M-$100M | 2 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 15 |
| Europe | 4 |
| Canada | 2 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Dolby Family Ventures | 5 |
| Brain Trust Accelerator Fund II | 2 |
| Cleveland Clinic | 2 |
| Eli Lilly and Company | 2 |
| Foundation for a Better World | 2 |
| Alexandria Venture Investments | 1 |
| Boston Harbor Angels | 1 |
| Centre for Aging + Brain Health Innovation | 1 |
| Clave Capital | 1 |
| CRUINT | 1 |
| DeepWork Capital | 1 |
| Dementia Discovery Fund | 1 |
| Dreavent Capital | 1 |
| EIC Fund | 1 |
| FoundersX Ventures | 1 |
| Gentex Corporation | 1 |
| Grand Angels | 1 |
| Health Innovation Pitch | 1 |
| IAG Capital Partners | 1 |
| iGan Partners | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 9 | 43% |
| Participating | 12 | 57% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 9 | 100% |
| Co-led | 0 | 0% |
Team
Founding Executive Director and Chief Science Officer
Co-Chairman & Co-Founder
Business Advisory Board & Scientific Review Board
Director
Co-Chairman and Co-Founder